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Sinus histiocytosis with massive lymphadenopathy (SHML) is
an idiopathic proliferation of unique histiocytes that have
vesicular nuclei and voluminous pale cytoplasm, often with
emperipolesis. Pure cutaneous involvement is very rare. We
describe a patient with SHML limited to the skin whose lesion
has spontaneously regressed. A 35-year-old Korean male visited
the Department of Dermatology due to facial rash for 2 months.
A 363.5 cm-sized well-demarcated dark erythematous non-
tender plaque was noted on the right cheek. Skin biopsy showed
dense, nodular infiltrates of histiocytes with abundant cytoplasm
and vesicular nuclei rimmed by lymphoplasma cell aggregates
throughout the upper and mid-dermis. The histiocytes were
immunohistochemically positive for S-100 protein and CD68,
but negative for CD1a. Laboratory tests and a thorough
physical examination revealed no abnormalities. These findings
suggested that this was a case of SHML clinically limited to the
skin. The skin lesion was initially resistant to steroid therapy,
but began to regress 10 months after the onset without further
treatment. Key words: sinus histiocytosis; skin.
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Sinus histiocytosis with massive lymphadenopathy (SHML)
was first described by Rosai & Dorfman (1) in 1969. The
prototype patient was a black child or adolescent with
persistent fever, prominent cervical lymphadenopathy and
associated haematological and immunological abnormalities.
At first, massive lymphadenopathy was regarded as a
hallmark of SHML, but experience with larger numbers of
patients has shown that lymphadenopathy is occasionally
lacking. Involvement of extranodal sites (skeleton (2), salivary
gland (3), central nervous system (4), eyes (5), upper
respiratory tracts (3, 6) and skin (7, 8)) have been documented
in approximately 30% of affected individuals. Cutaneous
infiltrates have been noted in 10%, but sinus histiocytosis
limited to the skin is very rare (9). We describe a patient with
sinus histiocytosis limited to the skin, whose skin lesion has
been regressed spontaneously.
CASE REPORT
A 35-year-old Korean male visited the Department of Dermatology,
Yonsei University College of Medicine due to facial rash for 2
months. Examination revealed a 363.5 cm-sized, well-demarcated,
dark erythematous non-tender plaque on the right cheek without any
lymphadenopathy (Fig. 1A). There was no fever, malaise, fatigue,
weight loss or other general symptoms. CBC, urinalysis, VDRL, anti-
nuclear antibody, liver function test, immunoelectrophoresis, Coombs
test, abdominal ultrasonogram and whole body bone scan were all
negative or within normal limits. IgG antibody for Epstein-Barr (EB)
virus nuclear antigen was positive, but IgG and IgM antibodies for
EB virus early antigen were negative. PPD skin test with 5 TU was
positive, but with 1 TU it was negative.
Skin biopsy demonstrated dense, nodular infiltrates of histiocytes
with an abundant, ill-defined border of cytoplasm and vesicular nuclei
throughout the upper and mid-dermis. Abundant plasma cells and
lymphocyte infiltrations were observed at the periphery of the lesion
(Fig. 2). Emperipolesis of lymphocytes was also found, but was not
prominent. Immunohistochemically, histiocytes were positive for S-
100 protein (Dako, Carpinteria, CA, USA) (Fig. 3) and CD 68 (KP1
and PGM1, Dako) but negative for CD1a (Immutech, France) and
CD 30 (Dako). The patient had previously received treatments with
dapsone for 2 months at local clinic without improvement before
Fig. 1. (A) A 363.5 cm-sized, well-demarcated, dark erythematous
non-tender plaque on the right cheek. (B) The size of the plaque
on the right cheek decreased to a 0.360.5 cm-sized papule with
surrounding erythema of 2.862.3 cm size 18 months after develop-
ment of the lesion.
Fig. 2. Histiocytes with abundant, ill-defined borders of cytoplasm
and vesicular nuclei (H & E6400).
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coming to our department. Thus, we started administration of
systemic steroids for 2 months, which also showed no effect. Then we
simply observed the patient for 14 months without any further
treatment. The size of the plaque on the right cheek started to
decrease 10 months after its onset. Now it was a mere 0.360.5 cm-
sized papule with surrounding erythema of 2.862.3 cm size (Fig. 1B).
Systemic symptoms were not observed during the 18 months of
follow-up. Follow-up studies, including CBC, liver function test,
immunoelectrophoresis, abdominal ultrasonograph and antibodies for
EB virus, were within normal limits or negative.
DISCUSSION
SHML is a well-established clinicopathological entity usually
developed in children or young adults (10). The clinical
spectrum includes nodal and extranodal disease. Extranodal
infiltrates, which occur in approximately 40% of patients (11),
have been documented in almost any organ, but the most
common sites of involvement appear to be the orbits, skin,
upper respiratory tract and bone. Those patients may have
fever or weight loss, and less commonly tonsillitis, nasal
discharge or nasal obstruction. Cutaneous lesions usually
consist of solitary or multiple papules or nodules of a
xanthomatous or erythematous hue ranging in size up to 4 cm
(8).
The laboratory findings are non-specific but hypergamma-
globulinaemia (usually polyclonal), as well as elevated anti-
body titres to EB virus, have been found in a considerable
proportion of patients, suggesting an impaired immune
response to an infectious agent or antigen (12). Our patient
had IgG antibody for EB virus nuclear antigen, but IgG and
IgM antibodies for EB virus early antigen were negative.
Thus, our patient did not show any significantly abnormal
laboratory findings.
The definitive diagnosis of SHML has always been based
on histopathological features. Foucar et al. (9) considered
emperipolesis and S-100 protein expression by histiocytes with
feathery border to be the main findings allowing a firm
diagnosis of SHML. In extranodal SHML, the morphological
features recapitulate to those of nodal disease. However,
accompanying fibrosis with vascular proliferation and less
prominent emperipolesis can make the diagnosis difficult. Chu
& LeBoit (13) have also stressed the histological features of
cutaneous SHML; the characteristic histiocytes admixed with
other inflammatory cells, emperipolesis, and thick-walled
venules surrounded by cuffs of plasma cells, especially at
the periphery of lesions. Our case also showed prominent
infiltration of the characteristic histiocytes with feathery
border, emperipolesis, numerous plasma cell infiltrations
and lymphoid aggregation.
The differential diagnoses of cutaneous SHML include
reticulohistiocytoma cutis, malignant histiocytosis, hemopha-
gocytic syndrome, Langerhans’ cell histiocytosis (14) and
CD30(z) T-cell lymphoma. Although S-100 protein expres-
sion (13) and leukophagocytosis (15) have been rarely
reported in reticulohistiocytoma cutis, the cytoplasm of the
proliferative histiocytes has a characteristic ground-glass
appearance with well-defined cell membranes and contains
abundant PAS-positive, diastase-resistant material. In addi-
tion, plasma cells are infrequent in contrast to SHML (13).
Malignant histiocytosis (16) shows pleomorphic nuclei and
frequent mitotic figures, but SHML lacks pleomorphism.
Haemophagocytic syndrome usually exhibits lobular panni-
culitis and the histiocytes do not express S-100 protein.
Phagocytosis is exceptional in Langerhans’ cell histiocytosis
(17) while the histiocytes show characteristic grooved nuclei
and eosinophils are commonly associated. Although some
nuclei with prominent nucleoli are seen in our case, we can
rule out the possibility of CD 30(z) pleomorphic T-cell
lymphoma due to negative results of CD30. Benign-appearing
histiocytes exhibiting leukophagocytosis can be seen in
erythema elevatum diutinum (18), Sweet’s syndrome (19)
and infectious disease. The clinical features of our case and
the lack of leukocytoclastic vasculitis and/or dermal neutro-
philic infiltration with nuclear dust excluded these diseases.
S-100 protein is expressed in various tissue, melanocytes,
nerves, eccrine glands and Langerhans’ cells (20, 21). Among
the histiocytoses, Langerhans’ cell histiocytosis, indetermi-
nated cell histiocytosis, congenital self-healing reticulohistio-
cytosis and SHML show S-100 protein-positive histiocytes
(20). Among them, SHML usually does not express CD1a in
contrast to the others (14). CD68 (KP1 and PGM1) is a
macrophage marker and dendritic lineage histiocytes do not
usually express this molecule. So the histological findings, as
well as the immunophenotype (S-100 proteinz, CD68z,
CD1a – ), fit well with the diagnosis of SHML.
SHML usually shows a benign clinical course, and an ideal
therapeutic option other than excision has not yet been
established. In some patients, the disease may be persistent
and progressive and associated immunological and haemato-
logical abnormalities have been reported to be an unfavour-
able sign predicting poor prognosis (22). The clinical course of
the reported pure cutaneous form of SHML is variable. Some
cases are persistent while others are self-healed, but there have
been no fatal cases. Our patient did not show any
abnormalities of immune function and no sign of systemic
involvement was detected. The lesion did not have any
response to dapsone and systemic corticosteroid treatment.
Therefore, we have followed the patient without further
treatment. Fortunately, his skin lesion has decreased in size to
0.360.5 cm 18 months after onset of the disease even without
any specific treatment. However, frequent physical examina-
tion and laboratory studies seem most appropriate at this
juncture until complete clearance is realized.
Fig. 3. Infiltrated histiocytes showing diffuse and strong positivity
for S-100 protein and some of them showing intracytoplasmic
emperipolesis of lymphocytes (arrow) (Immunohistochemical stain,
6400).
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